DaVita Inc (DVA)
80.51
+1.13
(+1.42%)
USD |
NYSE |
Mar 31, 14:40
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 7.278B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -30.75% |
| Valuation | |
| PE Ratio | 13.93 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.6647 |
| Price to Book Value | 10.22 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 12.53 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 51.10% |
News
Headline
Wire
Time (ET)
Yahoo
03/29 09:51
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/05/2023* | -- | Results | Q1 2023 | -- | 1.22 | -- | |
| 05/05/2023* | 17:00 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 02/22/2023 | -- | Results | Q4 2022 | 1.11 | 0.98 | 12.79% | |
| 02/22/2023 | 17:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 10/28/2022 | -- | Results | Q3 2022 | 1.45 | 1.76 | -17.59% | |
| 10/28/2022 | 08:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/01/2022 | 17:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/01/2022 | -- | Results | Q2 2022 | 2.30 | 2.08 | 10.45% |
*Estimated Date/Time
Earnings
Profile
| DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business. |
| URL | https://www.davita.com |
| Investor Relations URL | https://investors.davita.com |
| HQ State/Province | Colorado |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| Equity Style | Mid Cap/Value |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Feb. 22, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 30, 2023.
Fundamentals
| Revenue (TTM) | 11.61B |
| Total Expenses (TTM) | 10.30B |
| Net Income (TTM) | 560.40M |
| Total Assets (Quarterly) | 16.93B |
| Total Liabilities (Quarterly) | 14.70B |
| Shareholders Equity (Quarterly) | 712.33M |
| Cash from Operations (TTM) | 1.565B |
| Cash from Investing (TTM) | -630.35M |
| Cash from Financing (TTM) | -1.121B |
Ratings
Profile
| DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business. |
| URL | https://www.davita.com |
| Investor Relations URL | https://investors.davita.com |
| HQ State/Province | Colorado |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| Equity Style | Mid Cap/Value |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Feb. 22, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| DVA Tweets |